Chat with us, powered by LiveChat
Feugiat nulla facilisis at vero eros et curt accumsan et iusto odio dignissim qui blandit praesent luptatum zzril.
1 800 888-8888
Welcome to BrainSpark Health
+1 (888) 258-7584


How NAD Therapy Can Help Parkinson’s Disease

Parkinson’s disease (PD) neurological deterioration and the arising motor dysfunction are triggered by the formation of Lewy body and the death of dopaminergic neuronal within the substantia nigra. Impaired function of the mitochondrial and incorrect cellular metabolism of the reactive oxygen species are the two factors known to cause apoptosis which is related to PD.

What is Parkinson’s Disease?

Parkinson’s disease is the world second largest neurodegenerative illness among older adults. It is characterized by motor functionality disturbances such as bradykinesia, muscular rigidity, and resting tremors.

The part of the brain responsible for motor control (striatum) releases a compound known as nicotinamide adenine dinucleotide (NAD) which is said to ease PA symptoms. In a mouse study of the disease, it has also been clinically proven to reduce the neurons that produce dopamine. NAD is a substance that activates the action of an enzyme.

Research shows that the causative mechanism of Parkinson’s disease involves inactive mitochondria, genetics, and oxidative stress. These then trigger an imbalance between the ability of the cells to detoxify free radicals and the production of free radicals. The cellular and the molecular changes that occur destroy dopamine-producing neurons. This is the nerve cell that dies in PA.

Studies show that NAD is crucial in the metabolism of healthy cellular redox and the production of energy in the mitochondrial.

Case Study on NAD Therapy

In this case report, an 80-year-old patient diagnosed with Parkinson’s disease for 14 years had his symptoms documented over eight days of intravenous NAD therapy. He had no other psychiatric or health issues. This patient sought treatment for his PA at a clinic specialized in NAD therapy. On arrival he presented with severe hand tremors, the inability to write his name or hold objects, severely low social interaction, and peripheral hallucinations.

After two hours of the first NAD infusion, the tremors became unnoticeable and disappeared for the rest of the day. They only occurred again mildly in the evening. On the second day of treatment, some tremors were experienced the whole day, but there were notable improvements compared to the first day. The patient experienced an absence of visual hallucinations. On the third day, the patient experienced minor tremors the whole day.

The other two days that followed were given a break on treatment to monitor changes. On the first day of no treatment, mild shaking on the right limb in the morning was reported and minor tremors on both hands throughout the day. The day that followed without treatment, the tremors on both hands increased.

On the fourth day of treatment, mild tremors were reported throughout the day. On the fifth day, he still had minor tremors but could write well. Slight shaking on both thumbs was reported on day six of treatment only in the morning hours. The tremors then disappeared and did not recur the whole day. On day seven of NDA therapy, the tremors had disappeared entirely in the morning, but mild shaking occurred in the day.

In the morning of the eighth day of NAD therapy, only some peripheral hallucinations were reported. They, however, disappeared in the day. In this final day of treatment, only minor tremors that remained throughout the day could be felt. On his follow up PD maintenance, his neurological symptoms were seen to improve, and he discontinued his Parkinson’s disease medication.

Upon depending on NAD, he managed to live without visual hallucinations and reported to be leading a more meaningful and enjoyable life. The reduction noted in PD symptoms highlights a major anecdotal support for NAD therapy. While further research may be needed, this case study implies that NAD therapy is valuable in this neurodegenerative illness.

The Rodent Model

In a different study, Chinese researchers formed a team to investigate how NAD therapy would alleviate the motor deficits of Parkinson in a rodent model. Select animals were injected with NAD in their right striatum. This was done at least four hours before they were injected with 6-hydroxydopamine (6-OHDA) neurotoxin into the same part of the brain.

6-OHDA triggers the dysfunction of the cellular and destroys the dopaminergic neurons. In a lab setting, this function replicates PA. After the analysis was done, the NAD injection had reversed the loss of dopaminergic neurons.

Cell culture technology was then used by scientists to test if cells could be protected from the cellular and structural damage of 6-OHDA through the administration of NAD therapy. According to the results, there was enough proof that the viability of cells caused by 6-OHDA went down by 50 percent after NAD administration.

6-OHDA was found to cause alterations in cell morphology, impair mitochondrial function, and heighten the oxidative stress levels. Upon NAD pretreatment, all these were reversed. The findings add weight to the beneficial role of NAD in Parkinson’s disease. This suggests that NAD has the strength to prevent PA’s pathological changes.


Parkinson’s disease is a top cause of disability and death across the globe. Statistics show that at least 2 percent of men and women aged 65 and above are at risk, with its prevalence rising with age. Recent evidence shows that a deficiency in NAD is crucial in the pathogenesis of the disease.

Studies suggest that the best way to correct the metabolic defect and treat Parkinson’s disease is by increasing the levels of NAD. This could help in slowing down the progression of PD and boost the mitochondrial function. BrainSpark Health to this regard has followed one of the most rigorous paths to recovery, which is the brain and neuronal health.

After an assessment of your condition, our team will offer you NAD IV Therapy to boost cellular function, restore your NAD, reverse mitochondrial dysfunction, and enhance your wellbeing. With us, you can expect to see improved mental clarity, emotional balance, and mood in less than two weeks of repeated NAD IV therapy sessions.

We combine holistic approaches to treatment including social reprogramming and medication rather than just depending on the conventional mode of treatment which has been found to have 85 percent rate of failure. Reach out to BrainSpark today either online or at the clinic located in Plymouth Meeting, PA to find out if NAD therapy is right for you.